Tislelizumab shows favourable safety profile compared to sorafenib among liver cancer patients
News
Stada launches prostate cancer treatment across 21 European countries
Company is introducing abiraterone film-coated tablets for treating metastatic prostate cancer
Positive phase 3 data for Sanofi’s Dupixent
Research showed significant improvements in signs and symptoms of prurigo nodularis
Individuals Marketer of the Year 2022 categories still open!
You can still submit your entry before the imminent 16 September 2022 deadline – but hurry!
Still time to enter the 2022 Sales Awards!
Get started on your entry for these prestigious awards now – the deadline is 16 September 2022
Communication Awards entries still open!
Entering the singles categories is simple, quick and free, but hurry – the deadline is 16 September 2022
Valneva and VBI announce partnership for hepatitis B vaccine
Collaboration involves the marketing and distribution of PreHevbri across Europe
Neuroplast receives medicinal product designation for Neuro-Cells
Designation paves way for wider applications for several neurodegenerative diseases
UCB reveals new Bimzelx ‘complete skin clearance’ data
Positive data represents a boost for patients with moderate to severe plaque psoriasis
Brainomix and Bridge Biotherapeutics enter artificial intelligence partnership
Link up will utilise Brainomix’s AI software for the assessment of idiopathic pulmonary fibrosis
PhoreMost in drug target discovery collaboration with Roche
PhoreMost will use Siteseeker platform to identify novel targets for Roche’s discovery programmes
BioInnovation Institute reveals new cohort entering Venture Lab programme
Group consists of nine ventures plus corporate-sponsored innovation projects from Novo Nordisk
New PM will ‘inherit an NHS in its most challenging state for decades’
Warning comes from NHS leaders as new Prime Minister prepares to move into Number 10
Sanofi and Regeneron’s Dupixent shows consistent safety profile
Study involving children aged six to 11 years with moderate-to-severe asthma reveals positive data
First patient enrolled in Modus’ sevuparin trial
Research is evaluating the therapy among paediatric patients with severe malaria
